Quotient Bioscience Group Ltd. has acquired Pharmaceutical Profiles Group (PPG), which will be integrated into Quotient Bioresearch. Founded in 1990, Pharmaceutical Profiles is a  provider of Phase I drug development services to the global pharmaceutical and biotechnology industries. It offers an integrated formulation development, manufacturing and clinical testing platform incorporating a range of technologies, and covers the development of optimized oral, intravenous, and inhaled clinical dosage forms. It is based in Nottingham, UK and has 75 employees. The company will change its name to Quotient Bioresearch in the next year.

Its addition to Quotient’s unit will give the bioresearch business an “integrated metabolic sciences service offering, spanning radio synthesis through to human AME studies,” according to a Quotient statement.  It will also continue to build on PPG’s position in accelerated clinical formulation development. Mark Egerton will retain his role as managing director of Pharmaceutical Profiles, which will continue to operate from its existing Nottingham Phase I facility.

Pharmaceutical Profiles represents the fifth acquisition to date for Quotient, which was established in early 2007. The enlarged group will have revenues approaching $60 million and employ more than 450 people in the UK.  Quotient will continue to operate from its existing sites in Newmarket, Rushden, Nottingham, Edinburgh and London. 

Paul Cowan, chairman and chief executive officer of Quotient, said, “We are delighted to have completed the acquisition of Pharmaceutical Profiles.  It brings with it a world-class reputation and an innovative service offering, which we plan to expand.  It fits extremely well with our strategy of adding complementary drug development capabilities to the existing service offering of Quotient Bioresearch.”